Evidence map›Paper›PMID 11896616›Full record

ArticleOncogene2002

Absence of fibroblast growth factor 2 does not prevent tumor formation originating from the RPE.

Alessandro Foletti, Julien Ackermann, Andrea Schmidt, Edith Hummler, Friedrich Beermann

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Pax genes in embryogenesis and oncogenesis.Journal of cellular and molecular medicine · 2008
    Review
  4. Article
  5. Fibroblast growth factor 2.Differentiation; research in biological diversity
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Alessandro FolettiISREC (Swiss Institute for Experimental Cancer Research), Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland.
Julien Ackermann
Andrea Schmidt
Edith Hummler
Friedrich Beermann
Swiss Group For Clinical Cancer Research · CHUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have analysed the importance of fibroblast growth factor 2 (FGF2) in tumor development. In a transgenic mouse model (Tyrp1-Tag) tumors form in the retinal pigment epithelium (RPE), invade surrounding tissues, and metastasize to lymph node and spleen. To address whether RPE tumor formation is dependent on FGF2, we generated FGF2-deficient mice. Such mice appeared healthy and exhibited no impairment of growth or development. Tyrp1-Tag transgenic mice, which are lacking FGF2 (FGF2-/-) developed RPE tumors that metastasize to spleen and lymph nodes. Tumor growth and survival rate are identical to Tyrp1-Tag transgenic littermates expressing FGF2. Cell lines were isolated from RPE tumors of wild-type and FGF2-deficient mice. They grow in culture, are pigmented and form vascularized tumors, when injected subcutaneously into nude mice of either FGF2-/- or FGF2+/+ genetic background. Kinetics of tumor growth was identical and independent of presence of FGF2. Together, these results demonstrate that FGF2 is not essential for tumor formation of the RPE thus suggesting that tumor growth in general may not be dependent on FGF2.

Indexed as

OxidoreductasesAnimalsBlotting, WesternFemaleFibroblast Growth Factor 2MaleMelanomaMembrane GlycoproteinsMiceMice, Inbred C57BLMice, KnockoutMice, NudePigment Epithelium of EyeReverse Transcriptase Polymerase Chain ReactionRNATumor Cells, CulturedFibroblast Growth Factor 2Membrane GlycoproteinsOxidoreductasesRNATyrp1 protein, mouse

Identifiers

PMID11896616
OpenAlexW1979846314

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.